Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure.
Prospective, multicenter, observational study to evaluate the Merit WRAPSODY® Cell Impermeable Endoprosthesis for treatment of stenosis or occlusion within the dialysis outflow circuit (WRAP North America)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE) | Device | Target Lesion treated with WRAPSODY CIE |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint) | The proportion of subjects with Target Lesion Primary Patency (TLPP) at 6 months. Target Lesion Primary Patency (TLPP) defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or target lesion thrombosis measured through 6 months post-procedure, which is the time interval of uninterrupted patency after study procedure to the next intervention performed on the target lesion or uncorrectable target lesion occlusion. | 6 months |
| Proportion of subjects without any localized or systemic safety events (Primary Safety Endpoint) | Proportions of subjects without any localized or systematic safety events through 30 days post-procedure that affect the access or venous outflow circuit and resulted in reintervention, hospitalization, or death (not including CD-TLR or target lesion thrombosis) | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects with Target Lesion Primary Patency | Proportion of subjects with Target Lesion Primary Patency at months 12, 24 and 36. | 12, 24 and 36 months |
| Proportion of subjects with Assisted Target Lesion Primary Patency (aTLPP) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Subjects with stenosis or occlusion within the dialysis outflow circuit who meet the inclusion and exclusion criteria are intended to participate in this study. The eligibility criteria are kept to a minimum to better represent the subject profile treated in actual clinical practice without selecting sub-groups of particular low/high risk or excluding certain diseases or anatomies.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Irene Coughlin | Contact | +1-385-766-9133 | irene.coughlin@merit.com | |
| Vicky Brunk, RN | Contact | WRAP-NA@merit.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Trinity Research Group | Recruiting | Dothan | Alabama | 36301 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Proportion of subjects with Assisted Target Lesion Primary Patency (aTLPP)
| 6, 12, 24 and 36 months |
| Proportion of subjects with Access Circuit Primary Patency (ACPP) | Proportion of subjects with Access Circuit Primary Patency (ACPP) | 6, 12, 24 and 36 months |
| Rates of procedure- and device-related adverse events | Number of subjects with procedure- and device-related adverse events | Index procedure, 30 days, 6, 12, 24 and 36 months |
| AKDHC Phoenix Surgery Center | Recruiting | Phoenix | Arizona | 85016 | United States |
|
| Apex Research of Riverside | Recruiting | Riverside | California | 92505 | United States |
|
| American Access Care of Jacksonville | Recruiting | Jacksonville | Florida | 32218 | United States |
|
| Sarasota Memorial Research Institute | Recruiting | Sarasota | Florida | 34239 | United States |
|
| University of Kentucky | Recruiting | Lexington | Kentucky | 40536 | United States |
|
| American Access Care of Rhode Island | Recruiting | Providence | Rhode Island | 02906 | United States |
|
| Medical University of South Carolina | Recruiting | Charleston | South Carolina | 29425 | United States |
|
| Medical University of South Carolina | Recruiting | Orangeburg | South Carolina | 29118 | United States |
|
| Spartanburg Medical System | Recruiting | Spartanburg | South Carolina | 29303 | United States |
|
| Bluff City Vascular | Recruiting | Memphis | Tennessee | 38104 | United States |
|
| Texas Research Institute | Recruiting | Fort Worth | Texas | 76104 | United States |
|
| Humble Vascular Surgical Center | Recruiting | Humble | Texas | 77338 | United States |
|
| San Antonio Kidney Disease Center | Recruiting | San Antonio | Texas | 78216 | United States |
|
| Sentara Vascular Specialists | Recruiting | Virginia Beach | Virginia | 23507 | United States |
|
| University Health Network | Recruiting | Toronto | Ontario | M5G 2C4 | Canada |
|
| ID | Term |
|---|---|
| D001164 | Arteriovenous Fistula |
| ID | Term |
|---|---|
| D001165 | Arteriovenous Malformations |
| D054079 | Vascular Malformations |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D016157 | Vascular Fistula |
| D014652 | Vascular Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D005402 | Fistula |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided